You just read:

Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15

News provided by

Relmada Therapeutics, Inc.

Oct 14, 2019, 16:49 ET